HLA Typing for Transplant Market by Product & Service (Instruments, Reagents & Consumables, Software & Services), Technology (Molecular Assay Technologies, Non-Molecular Assay Technologies), Transplant Type, Application, End-User - Global Forecast 2024-20

HLA Typing for Transplant Market by Product & Service (Instruments, Reagents & Consumables, Software & Services), Technology (Molecular Assay Technologies, Non-Molecular Assay Technologies), Transplant Type, Application, End-User - Global Forecast 2024-2030

The HLA Typing for Transplant Market size was estimated at USD 998.31 million in 2023 and expected to reach USD 1,086.39 million in 2024, at a CAGR 9.09% to reach USD 1,836.58 million by 2030.

Human leukocyte antigen (HLA) typing is a vital process in medicine transplant that involves identifying specific proteins on the surface of cells, known as HLA antigens. The HLA typing for the transplant is used to identify, match, and monitor compatibility between donors and recipients for organ, tissue, or stem cell transplantation. This process is crucial to ensure a successful transplant by reducing the risk of graft rejection and improving overall patient outcomes. Moreover, the rising demand for organ transplants is due to an increase in chronic diseases such as kidney failure, liver cirrhosis, heart failure, diabetes mellitus, and hematological disorders. Precision medicine advancements can lead to personalized approaches based on individual genetic makeup for improved compatibility between donors and recipients. However, there is a need for more trained professionals performing these tests and ethical concerns surrounding organ transplantation consent policies, which restrict the growth of the Human leukocyte antigen (HLA) processes. Furthermore, technological advancements in HLA typing methods such as Next-Generation Sequencing (NGS), PCR-based techniques, and Sanger sequencing contribute to improved accuracy and a faster donor-recipient matching process. Government support through awareness campaigns promoting organ donation and investments in healthcare infrastructure further drive market expansion.

Regional Insights

The Human leukocyte antigen (HLA) typing for transplant market is experiencing significant growth worldwide due to technological advancements and the availability of numerous organ transplant procedures. In the United States and Canada, demand for HLA typing is increasing due to growing organ transplantation needs. The National Institutes of Health (NIH) in the U.S. has funded numerous research initiatives to improve HLA typing techniques. Moreover, the Americas human leukocyte antigen (HLA) typing market is expected to grow at a higher rate due to increasing awareness about organ transplantation among both physicians and patients, along with technological advancements leading to more accurate HLA typing results. Europe has witnessed a steady increase in demand for HLA typing services owing to factors such as an aging population that increases the prevalence of chronic diseases requiring organ transplantation. Additionally, favorable reimbursement policies have supported patients undergoing transplant procedures in Europe. Organizations such as the Saudi Society for Organ Transplantation (SSOT) are working to increase awareness and collaborations between nations, such as the Gulf Cooperation Council (GCC) Organ Transplant Program. China, Japan, and India are witnessing an increased demand for HLA typing due to a high prevalence of genetic disorders and growing organ transplantation needs. China's National Natural Science Foundation has funded research on novel HLA typing techniques. Moreover, Japan's Ministry of Health, Labor, and Welfare supports projects such as the Japan Society for Transplantation and Cellular Therapy (JSTCT). In India, government initiatives, such as the 'National Organ and Tissue Transplant Organization (NOTTO) contribute to market growth by increasing public awareness about organ donation.

Market Insights

• Market Dynamics
  
  The market dynamics represent an ever-changing landscape of the HLA Typing for Transplant Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising incidence of bone marrow, organ, and blood transplant processes
    • Adoption of HLA typing in personalized medicine for reduced graft rejections
    • Market Restraints
      • Lack of reimbursement and inadequate insurance policies
      • Market Opportunities
        • Technological advancements in the field of transplant diagnostics and HLA-typing methods
        • Preference for immunosuppressive therapies to complement HLA typing
        • Market Challenges
          • Concerns regarding the inaccuracy of HLA typing
          • Market Segmentation Analysis
            • Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
            • Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
            • Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
            • Application: Use of HLA typing in diagnostic applications for organ transplantation
            • End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
            • Market Disruption Analysis
            • Porter’s Five Forces Analysis
            • Value Chain & Critical Path Analysis
            • Pricing Analysis
            • Technology Analysis
            • Patent Analysis
            • Trade Analysis
            • Regulatory Framework Analysis
            FPNV Positioning Matrix
            
            The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the HLA Typing for Transplant Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
            
            Market Share Analysis
            
            The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the HLA Typing for Transplant Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
            
            Recent Developments
            • GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
              
              GenDx introduced their latest offering, NGS-Turbo, designed to provide high-resolution HLA typing using Oxford Nanopore Technologies sequencing devices. This product provides high speed and efficiency, making it ideal for time-sensitive transplantation testing.
              
              Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
              
              Omixon Biocomputing Ltd. launched NanoTYPE MONO and MONO all RUO, a single locus HLA amplification kit that is fully compatible with Oxford Nanopore's MinION platform. This technology has been specifically designed to provide clinical laboratories with the capability to retype, confirm, and analyze single HLA genes with remarkable accuracy and precision at a competitive price.
              
              JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
              
              JURA Bio announced a partnership with Syena to advance the development of innovative therapies by leveraging JURA Bio's T cell receptor (TCR) discovery platform, which incorporates AI and machine learning techniques. In addition to this partnership, JURA Bio has secured USD 16.1 million in financing. This funding is expected to contribute to the mapping of the adaptive immune system, allowing for the creation of a predictive map of TCR-antigen-HLA binding.
            Strategy Analysis & Recommendation
            
            The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the HLA Typing for Transplant Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
            
            Key Company Profiles
            
            The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BAG Diagnostics GmbH, Becton, Dickinson, and Company, BGI Genomics Co.,Ltd., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, CapitalBio Technology Co., Ltd., CareDx, Inc., CeGaT GmbH, Chugai Pharmaceutical Co., Ltd., Creative Biolabs, Inc., DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffman-La Roche AG, Fujirebio, Inc. by H.U. Group Holdings, Inc., Garuda Therapeutics, GenDx by Eurobio Scientific Group, HEALIOS K.K., Hologic, Inc., Illumina, Inc., Immatics N.V., Immucor, Inc. by Werfen, S.A., ImmunOs Therapeutics AG, Invectys Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Merck KGaA, NeoGenomics Laboratories, Inc., OraSure Technologies, Inc., Oxford Nanopore Technologies PLC, Pure MHC, LLC, Pure Protein, LLC, QIAGEN N.V., STEMCELL Technologies Inc., T-Cure Bioscience Inc., Takara Bio Inc., TBG Diagnostics Ltd., TCR² Therapeutics by Adaptimmune Therapeutics PLC, and Thermo Fisher Scientific, Inc..
            
            Market Segmentation & Coverage
            
            This research report categorizes the HLA Typing for Transplant Market to forecast the revenues and analyze trends in each of the following sub-markets:
            • Product & Service
              • Instruments
              • Reagents & Consumables
              • Software & Services
              • Technology
                • Molecular Assay Technologies
                  • PCR-Based Molecular Assays
                    • Real-Time PCR
                    • Sequence-Specific Oligonucleotide-PCR
                    • Sequence-Specific Primer-PCR
                    • Sequencing-Based Molecular Assays
                      • Next-Generation Sequencing
                      • Sanger Sequencing
                      • Non-Molecular Assay Technologies
                      • Transplant Type
                        • Organ Transplantation
                        • Stem Cell Transplantation
                        • Tissue Transplantation
                        • Application
                          • Diagnostic Applications
                            • Antibody Screening
                            • Chimerism Monitoring
                            • Research Applications
                            • End-User
                              • Clinical Laboratories & Research Institution
                              • Hospitals & Transplant Centers
                              • Independent Reference Laboratories
                              • Region
                                • Americas
                                  • Argentina
                                  • Brazil
                                  • Canada
                                  • Mexico
                                  • United States
                                    • California
                                    • Florida
                                    • Illinois
                                    • New York
                                    • Ohio
                                    • Pennsylvania
                                    • Texas
                                    • Asia-Pacific
                                      • Australia
                                      • China
                                      • India
                                      • Indonesia
                                      • Japan
                                      • Malaysia
                                      • Philippines
                                      • Singapore
                                      • South Korea
                                      • Taiwan
                                      • Thailand
                                      • Vietnam
                                      • Europe, Middle East & Africa
                                        • Denmark
                                        • Egypt
                                        • Finland
                                        • France
                                        • Germany
                                        • Israel
                                        • Italy
                                        • Netherlands
                                        • Nigeria
                                        • Norway
                                        • Poland
                                        • Qatar
                                        • Russia
                                        • Saudi Arabia
                                        • South Africa
                                        • Spain
                                        • Sweden
                                        • Switzerland
                                        • Turkey
                                        • United Arab Emirates
                                        • United Kingdom
                                        
                                        
                                        Please Note: PDF & Excel + Online Access - 1 Year